Popular terms

Leukemia topics
Myelogenous
Myelogenous Leukemia
Proliferative
Autoimmune
Stem Cells
Breast Cancer
Rheumatoid Arthritis
Myeloid Leukemia
Acute Myelogenous Leukemia
Lymphocytic
Chronic Lymphocytic Leukemia
Lymphocytic Leukemia
Epigenetic
Multiple Myeloma
Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukemia patents



      

This page is updated frequently with new Leukemia-related patent applications.




Date/App# patent app List of recent Leukemia-related patents
06/23/16
20160176978 
 Methods of manipulating phagocytosis mediated by cd47 patent thumbnailMethods of manipulating phagocytosis mediated by cd47
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..

06/23/16
20160176976 
 Methods of manipulating phagocytosis mediated by cd47 patent thumbnailMethods of manipulating phagocytosis mediated by cd47
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..

06/23/16
20160176876 
 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer patent thumbnail2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
The present invention provides 2-substituted imidazo[4,5-d]phenanthroline compounds, which are capable of inhibiting proliferation of one or more renal cancer cells, pancreatic cancer cells, prostate cancer cells, colon cancer cells, leukemia cells, brain cancer/tumour cells or non-small cell lung cancer cells.. .

06/23/16
20160175331 
 Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents patent thumbnailTreatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and art-838.

06/23/16
20160175320 
 Compositions, methods and kits for treating cancer patent thumbnailCompositions, methods and kits for treating cancer
Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ12-prostaglandin j3 or a derivative thereof, or a prostaglandin d receptor (dp) agonist. The compositions may further include a second anti-cancer drug.

06/23/16
20160175293 
 Pim kinase inhibitor combinations patent thumbnailPim kinase inhibitor combinations
The present invention relates to a pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a jak inhibitor compound, (b) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human..

06/16/16
20160168121 
 Quinoline derivative patent thumbnailQuinoline derivative
A compound represented by general formula (i) has a strong axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.. .
Ono Pharmaceutical Co., Ltd.


06/16/16
20160166579 
 Combination methods for treating cancers patent thumbnailCombination methods for treating cancers
Or a pharmaceutically acceptable salt thereof; in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy.

06/09/16
20160159739 
 Azacyclic constrained analogs of fty720 patent thumbnailAzacyclic constrained analogs of fty720
Small molecules comprised of azacyclic constrained analogs of fty720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases.
The Regents Of The University Of California


06/09/16
20160158245 
 Pharmaceutical formulation containing thienotriazolodiazepine compounds patent thumbnailPharmaceutical formulation containing thienotriazolodiazepine compounds
A method of treating lymphoblastic leukemia, acute myeloid leukemia, bcr-abl positive acute lymphoblastic leukemia or cd34 positive acute myeloid leukemia comprising the step of administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound according to formula (1) as a solid dispersion wherein x is a halogen, r1 is c1-c4 alkyl, r2 is c1-c4 alkyl, a is an integer of 1-4, r3 is c1-c4 alkyl, c1-c4 hydroxyalkyl, c1-c4 alkoxy, phenyl optionally having substituent(s), or heteroaryl optionally having substituent(s), a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hpmcas..
Oncoethix Gmbh


06/09/16
20160158219 

Use of an h4 agonist molecule to treat acute leukemia


The present invention relates to the use of new chemical substances, the levogyre and dextrogyre enantiomers of (amino-7 triethoxy-4, 5, 6 oxo-1 dihydro-1, 3 isobenzofurannyl-3)-1 methoxy-8 methyl-2methylenedioxy-6, 7 tetrahydro-, 2, 3, 4 isoquinoleine or tritoqualine, to treat acute myeloid or lymphoid leukemia, with the exception of type b leukemia.. .
Chrysalis Pharma


06/02/16
20160152724 

A new fusion protein to target and treat acute myloid leukemia cells


A polypeptide which binds to the surface of aml blast cells and is internalised upon binding to the aml blast cells.. .
Rheinisch-westfaelische Technische Hochschule Aachen


05/26/16
20160146788 

Method for screening drugs for treating/preventing myelodysplastic syndrome, etc.


(b) a step of selecting the test substance as a candidate for a therapeutic or prophylactic drug for acute myeloid leukemia or myelodysplastic syndrome and the like when the colony number in the presence of the test substance increases from the colony number in the absence of the test substance.. .

05/26/16
20160145692 

Methods and compositions involving lincrna and leukemia


The instant disclosure relates to the finding that lincrna expression is associated with particular cytogenetic abnormalities and is related to disease pathogenesis of certain cancers. Long intergenic non-coding rnas (lincrnas) have been found to play a role in gene regulation, but their expression has not been described in b acute lymphoblastic leukemia (b-all).
The Regents Of The University Of California


05/26/16
20160145337 

Cd19 specific chimeric antigen receptor and uses thereof


The present invention relates to chimeric antigen receptors (car). Cars are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties.
Cellectis


05/26/16
20160145264 

Novel lipophilic n-substituted norcantharimide derivatives and uses thereof


Novel n-substituted norcantharimide derivatives are disclosed herein. The novel n-substituted norcantharimide derivatives are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating cancer, particularly for treating leukemia..
Mackay Memorial Hospital


05/26/16
20160145258 

Inhibitor crystalline form and preparation method and use thereof


The present invention relates to a new crystalline forms of the inhibitor, 5-fluoro-3-phenyl-2-[(s)-1-(9h-purin-6-ylamino)-propyl]-3h-quinazoline-4-one; the new crystalline form, compared to known forms, has one or more improved properties. The present invention also relates to a method for preparing a new crystalline form of 5-fluoro-3-phenyl-2-[(s)-1-(9h-purin-6-ylamino)-propyl]-3h-quinazolin-4-one, a pharmaceutical composition thereof and a use thereof in preparation of a pharmaceutical for the treatment and/or prevention of diseases such as chronic lymphocytic leukemia and indolent non-hodgkin's lymphoma..
Hangzhou Pushai Pharmaceutical Technology Co., Ltd.


05/26/16
20160145206 

N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use


The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (copd); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as behçet's disease.
Pimco 2664 Limited


05/19/16
20160138115 

Methods and characteristics for the diagnosis of acute lymphoblastic leukemia


Methods for identification of leukemia or a genetic predisposition to leukemia are provided that are particularly applicable to acute lymphoblastic leukemia (all). A novel heterozygous germline variant, c.547g>a (p.gly183ser) in the octapeptide domain of pax5, is used to identify those individuals with an enhanced risk or predisposition to all..
Memorial Sloan-kettering Cancer Center


05/19/16
20160137630 

Induction of gata2 by hdac1 and hdac2 inhibitors


Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with gata2 deficiency, particularly diseases or disorders that involve any type of hdac1 and/or hdac2 expression. Such diseases include acute myeloid leukemia (aml); familial myelodysplastic syndrome (mds); leukemia; sickle-cell anemia; beta-thalassemia; monocytopenia and mycobacterial infections; dendritic cell, nonocyte, b, and natural killer lymphoid deficiency; emberger syndrome; asymptomatic neurocognitive impairment; mild neurocognitive disorder; and hiv-associated dementia..
Acetylon Pharmaceuticals, Inc.


05/19/16
20160136218 

Molecular and herbal combinations for disease therapy


A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination including emodin or digoxin, or both, with sheng di huang or da huang, or both, and/or jin yin hua.. .
Sirbal Ltd.


05/12/16
20160131654 

Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma


The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or b-cell non-hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting bcma in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or b-cell non-hodgkin lymphoma in the subject..
Institute For Myeloma & Bone Cancer Research


05/12/16
20160130665 

Prognostic methods and systems for chronic lymphocytic leukemia


The present invention provides systems useful for risk stratification of chronic lymphocytic leukemia (cll) patients. The systems can include a microarray and a decision tree having steps for stratification of one or more cll patients into prognostic groups.
Cancer Genetics, Inc.


05/12/16
20160130659 

Compositions and methods for treating cancer


The instant invention relates to methods for the treatment of b-cell lymphomas and leukemia by administering a syk inhibitor. In another embodiment, the invention relates to a method for treating a patient diagnosed with a b-cell lymphoma or leukemia, comprising administering a syk inhibitor, wherein the b-cells of said patient to be treated are characterized by elevated expression levels of cd86..
Merck Sharp & Dohme Corp.


05/12/16
20160130582 

Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof


The present invention provides, among other things, oligonucleotide modulators (e.g., inhibitors) of b cell lymphoma/leukemia 11a (bcl11a) and improved methods and composition for treating bcl11a-related diseases, disorders or conditions based on such modulators.. .
Roche Innovation Center Copenhagen A/s


05/12/16
20160130317 

Il-12 immunotherapy for cancer


Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems.
University Health Network


05/05/16
20160122334 

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

05/05/16
20160122323 

Inhibitors of cyclin-dependent kinase 7 (cdk7)


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


04/28/16
20160115468 

Albumin-binding arginine deiminase for cancer targeting treatment and detection of arginine


The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (aad) fusion protein for treating cancer or other arginine-dependent diseases. The aad fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (hsa) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells.
Vision Global Holdings Ltd.


04/28/16
20160115238 

Cd20 antibodies and uses thereof


Cd20 is a transmembrane protein of the tetra-spanin family expressed on the surface of b-cells from peripheral blood as well as lymphoid tissues. Cd20 expression persists from the early pre-b cell stage until the plasma cell differentiation stage.
Immunogen, Inc.


04/28/16
20160114018 

Imp-3 epitope peptides for th1 cells and vaccines containing the same


Isolated imp-3-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


04/21/16
20160108477 

Traceability of cellular cycle anomalies targeting oncology and neurodegeneration


The present invention relates to the field of medicine and biology. It concerns a novel test for screening and for therapeutic follow-up in oncology.

04/21/16
20160108360 

Genetic modification of rats


Compositions and methods are provided for making rat pluripotent and totipotent cells, including rat embryonic stem (es) cells. Compositions and methods for improving efficiency or frequency of germline transmission of genetic modifications in rats are provided.

04/21/16
20160108126 

Cd20 antibodies and uses thereof


Cd20 is a transmembrane protein of the tetra-spanin family expressed on the surface of b-cells from peripheral blood as well as lymphoid tissues. Cd20 expression persists from the early pre-b cell stage until the plasma cell differentiation stage.

04/21/16
20160108033 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.

04/21/16
20160108031 

Inhibitors of nhr2 and/or runx1/eto-tetramerization


The invention relates to inhibitors of the nhr2 tetramerization and their use as tumor therapeutics (e.g. Against acute myeloid leukemia (aml)), cytostatics, and diagnostic agents..

04/21/16
20160106731 

Tricyclic indole mcl-1 inhibitors and uses thereof


The present invention provides for compounds that inhibit the activity of an anti-apoptotic bcl-2 family member myeloid cell leukemia-1 (mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of mcl-1 protein..

04/07/16
20160097770 

Methods for diagnosis, prognosis and methods of treatment


This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g.
Nodality, Inc.


04/07/16
20160096825 

Furanone compounds as kinase inhibitors


The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as raf kinase, especially braf kinase, inhibitors, which are useful therapeutic agents for treatment of raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds..
Eternity Bioscience Inc.


04/07/16
20160096820 

Inhibitors of inv(16) leukemia


This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (aml). The inv(16) fusion results in expression of the cbfβ-smmhc fusion protein in the blood cells of afflicted patients.
University Of Virginia Patent Foundation


04/07/16
20160095870 

Methods of forming cyclopirox or derivatives thereof in a subject by administration of prodrug


A method of forming a compound in a subject can include: providing a composition having a prodrug compound represented by a structure of formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the composition to a subject such that the prodrug compound has a phosphoryloxyalkyl prodrug moiety removed therefrom to form the compound in the subject and to form the separate phosphoryloxyalkyl compound. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, various cancers (e.g., bladder, breast, etc.), dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum, and microsporum canis, candidiasis (moniliasis), candida albicans, tinea (pityriasis) vesicolor, malassezia furfur, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma..
The University Of Kansas


04/07/16
20160095863 

Combination treatment of acute myeloid leukemia and myelodysplastic syndrome


The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with quizartinib or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).. .
Boehringer Ingelheim International Gmbh


03/31/16
20160090637 

Pharmacogenomic biomarkers for b cell malignancies and methods of use thereof


The present invention relates to diagnosing drug-resistant chronic lymphocytic leukemia (cll) in a mammal.. .

03/24/16
20160083361 

Inhibitors of the ire-1/xbp-1 pathway and methods of using thereof


Disclosed are xbp-1/ire-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular b cell cancers, are also disclosed.
H. Lee Moffitt Cancer Center And Research Institute, Inc.


03/24/16
20160082071 

Methods of treating myeloid leukemia


There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a cxcr4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent..
Biokine Therapeutics Ltd.




Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.1397

5192

1 - 1 - 101